Skip to main content

New BIIE research institute established in Basel

| News

New BIIE research institute established in Basel


The Botnar Institute of Immune Engineering has been founded in Basel. The research location Basel managed to hold off competition from locations in the USA, England, Israel and Singapore to secure this important upgrade to its life sciences ecosystem. The research institute is planned to be hosted at the ETH Zurich site in Basel. In 2027, it will move into a new building on the Main Campus of the Switzerland Innovation Park Basel Area in Allschwil.

The BIIE is currently located in the D-BSSE in Basel. In 2027, the research institute will move into a new building on the Main Campus of the Switzerland Innovation Park Basel Area in Allschwil (Visualization: Herzog & de Meuron)

The Botnar Institute of Immune Engineering (BIIE) is starting out in Basel as an independent research institute. According to a press release, its aim is to develop novel immune-based diagnostics and therapeutics, as well as to close gaps in modern healthcare technologies in order to improve the health of children and young people around the world. For now, the BIIE is planned to be hosted by the Department of Biosystems Science and Engineering (D-BSSE), a Basel-based division of the Swiss Federal Institute of Technology in Zurich (ETH). In 2027, the BIIE is expected to move to the Main Campus of the Switzerland Innovation Park Basel Area in Allschwil in the canton of Basel-Landschaft.

A donation of more than 1 billion US dollars across a period of 15 years from the Basel-based philanthropic foundation Fondation Botnar is making the BIIE possible. The new institute will significantly enhance Basel’s reputation as a research hub and complement research groups already working at the D-BSSE and the Department of Biomedicine at the University of Basel. The region is home to more than 40 biotech and pharmaceutical companies active in the field of immunology. In addition to large corporations such as Roche and Novartis, startups like Engimmune Therapeutics, Anaveon and Cimeio Therapeutics are also dedicated to this field of research.

The new institute, which will have global appeal and reach, is set to employ 300 staff in the medium term. The process of recruiting researchers has already been initiated. Moreover, as the press release from Fondation Botnar indicates, plans are in place to agree partnerships with the University of Oxford and ETH. Basel’s application emerged successful against three locations in the USA, as well as against the “Golden Triangle” of London, Oxford, Cambridge in England, as well as Tel Aviv and Singapore.

Huge win for the Basel Area

“The BIIE will bring together a critical mass of investigators, all of whom are experts in various aspects of immune engineering; combining their strengths and perspective should result in a sum greater than its parts”, as Stephen Wilson, CEO of the BIIE and former Chief Operating Officer of the La Jolla Institute for Immunology in the USA, explains in the press release.

“The thriving cluster at the Switzerland Innovation Park Basel Area in Allschwil is the ideal location for the BIIE”, comments Monica Gschwind, head of government of the canton of Basel-Landschaft. Her counterpart from the cantonal government of the canton of Basel-Stadt, Conradin Cramer, describes Basel as a “strong economic region with a strong philanthropic tradition”. The focus of the new Botnar Institute of Immune Engineering on “people with the greatest need, as well as the entrepreneurial and humanistic mission of the new institute, are, in addition to the benefits for the life sciences cluster, a great signal to the wider world”.

“The BIIE is a huge win for the Basel region. Our life sciences hub is not only being expanded to include a significant field of research, but its standing in terms of the world’s most important research locations is also being bolstered”, comments Christof Klöpper, CEO of the investment and innovation promotion agency Basel Area Business & Innovation.

You may also be interested in

Roche investing an additional 1.2 billion Swiss francs in Basel

Roche will be putting an additional 1.2 billion Swiss francs towards the renovation of its site in Basel. This investment...
Read More

Nouscom secures 67.5 million euros in financing

Biotech company Nouscom has raised 67.5 million euros in a series C financing round. The Basel-based firm intends to use...
Read More

How open innovation in healthtech hubs is fueling the rise of digital healthcare

How the ever-increasing uptake of digital solutions is enhancing patient engagement, increasing access to care and lowering the cost of...
Read More

Paradigm shift in pain management

Pain is a crucial sensation for survival, but it can also drive us to depression and long-term suffering if not...
Read More

Investors stump up 3.7 million Swiss francs in Onena Medicines

Onena Medicines has secured an investment of 3.7 million Swiss francs. The portfolio company of the biotech startup incubator BaseLaunch...
Read More

Do you have a question? We'd like to hear from you.